Announcement for OBIGEN that its Phase 2 study for OBI-858 received positive final results and met primary and secondary endpoints with statistical significance

Date of occurrence of the event:2025/08/26 New drug name or code:OBI-858 Novel Botulinum Neurotoxin Indication: OBI-858 is a novel botulinum neurotoxin (BoNT) developed using OBIGEN’s proprietary bacteria, intended for both aesthetic and therapeutic applications. The product is characterized by a unique molecular weight and patents have been granted in multiple countries, including the US, Taiwan, […]